Grufity logo
Grufity logo
IMUX

IMUX - Immunic Inc Stock Price, Fair Value and News

$13.04-0.30 (-2.25%)
Market Closed as of 29 Jul 2026, 04:00 pm ET

Price Targets

IMUX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMUX Price Action

Last 7 days

-13.7%

Last 30 days

-15.4%

Last 90 days

35.6%

Trailing 12 Months

33.2%

IMUX RSI Chart

IMUX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMUX Valuation

Market Cap

177.6M

Price/Earnings (Trailing)

-1.7

Price/Sales (Trailing)

11.81

EV/EBITDA

-0.42

Price/Free Cashflow

-2.18

IMUX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

IMUX Fundamentals

IMUX Revenue

Revenue (TTM)

17.3M

IMUX Earnings

Earnings (TTM)

-104.3M

Earnings Growth (Yr)

-27.93%

Earnings Growth (Qtr)

-68.85%

IMUX Profitability

EBT Margin

-240.43%

Return on Equity

-68.96%

Return on Assets

-54.96%

Free Cashflow Yield

-45.85%

IMUX Investor Care

Dividend Yield

0%

Dividend/Share (TTM)

0

Shares Dilution (1Y)

34.41%

Diluted EPS (TTM)

-4.92

Revenue & Growth

How Immunic Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2021---17.3M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Immunic Inc

IMUX
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
 CEO
 WEBSITEimux.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES75

Immunic Inc Frequently Asked Questions

IMUX is the stock ticker symbol of Immunic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jul 29 2026, market cap of Immunic Inc is 177.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jul 29 2026, IMUX's PE ratio (Price to Earnings) is -1.7 and Price to Sales (PS) ratio is 11.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMUX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Immunic Inc has provided -0.408 (multiply by 100 for percentage) rate of return.